Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, budesonide (Jorveza®) cannot be endorsed for use within NHS Wales as maintenance therapy for eosinophilic esophagitis in adults (older than 18 years of age). Budesonide (Jorveza®) was considered suitable for limited assessment by the AWMSG Scrutiny Panel at their meeting on 03/11/2025. |
||
|
||
Medicine details |
||
| Medicine name | budesonide (Jorveza®) | |
| Formulation | 0.5 mg and 1 mg orodispersible tablet | |
| Reference number | 4507 | |
| Indication | As maintenance therapy for eosinophilic esophagitis in adults |
|
| Company | Dr Falk Pharma UK Ltd | |
| BNF chapter | Gastro-intestinal system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Scrutiny Panel meeting date | 03/11/2025 | |
| Date of issue | 24/09/2020 | |
| Further information Budesonide (Jorveza®) was considered suitable for limited assessment by the AWMSG Scrutiny Panel at their meeting on 03/11/2025. The assessment will consider the evidence for clinical effectiveness and budget impact. AWTTC will engage with clinicians across NHS Wales to gather further intelligence on the proposed treatment pathway and patient population. The company will be invited to submit for a limited assessment, and / or to share any relevant insights to facilitate the assessment. |
||